Schally AV - Search Results

1

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.

Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Plonowski A, et al. Among authors: schally av. Cancer Lett. 2002 Feb 8;176(1):57-63. doi: 10.1016/s0304-3835(01)00734-0. Cancer Lett. 2002. PMID: 11790454

2

Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.

Radulovic S, Nagy A, Szoke B, Schally AV. Radulovic S, et al. Among authors: schally av. Cancer Lett. 1992 Mar 15;62(3):263-71. doi: 10.1016/0304-3835(92)90105-5. Cancer Lett. 1992. PMID: 1317746

3

Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats.

Pinski J, Yano T, Groot K, Milovanovic S, Schally AV. Pinski J, et al. Among authors: schally av. Peptides. 1992 Sep-Oct;13(5):905-11. doi: 10.1016/0196-9781(92)90048-8. Peptides. 1992. PMID: 1336188

4

Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.

Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV. Yano T, et al. Among authors: schally av. Prostate. 1992;20(4):297-310. doi: 10.1002/pros.2990200405. Prostate. 1992. PMID: 1351672

5

Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.

Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV. Szepeshazi K, et al. Among authors: schally av. Breast Cancer Res Treat. 1992;21(3):181-92. doi: 10.1007/BF01975001. Breast Cancer Res Treat. 1992. PMID: 1355375

6

Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.

Schally AV, Comaru-Schally AM, Gonzalez-Barcena D. Schally AV, et al. Biomed Pharmacother. 1992;46(10):465-71. doi: 10.1016/0753-3322(92)90004-q. Biomed Pharmacother. 1992. PMID: 1363977 Review.

7

Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats.

Pinski J, Yano T, Schally AV. Pinski J, et al. Among authors: schally av. Neuroendocrinology. 1992 Dec;56(6):831-7. doi: 10.1159/000126313. Neuroendocrinology. 1992. PMID: 1369591

8

Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.

Milovanovic SR, Radulovic S, Groot K, Schally AV. Milovanovic SR, et al. Among authors: schally av. Prostate. 1992;20(4):269-80. doi: 10.1002/pros.2990200403. Prostate. 1992. PMID: 1376910

9

Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.

Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T. Szepeshazi K, et al. Among authors: schally av. Anticancer Drugs. 1992 Apr;3(2):109-16. doi: 10.1097/00001813-199204000-00006. Anticancer Drugs. 1992. PMID: 1388062

10

Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.

Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV. Yano T, et al. Among authors: schally av. Breast Cancer Res Treat. 1992;21(1):35-45. doi: 10.1007/BF01811962. Breast Cancer Res Treat. 1992. PMID: 1391973

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,459 results

Search Page

Filters